Company Profile: Pacific Diabetes Technologies Inc.
Background
Pacific Diabetes Technologies Inc. (PDT) is a Portland, Oregon-based medical device company founded in 2013. The company is dedicated to revolutionizing diabetes management by developing innovative devices that integrate continuous glucose monitoring (CGM) and insulin delivery into a single, user-friendly system. This approach aims to simplify the daily routines of individuals with insulin-dependent diabetes, thereby improving health outcomes and quality of life.
Key Strategic Focus
PDT's strategic focus centers on:
- Core Objectives: Developing advanced medical devices that combine CGM and insulin delivery to streamline diabetes management.
- Areas of Specialization: Medical device manufacturing, particularly in the field of diabetes care.
- Key Technologies Utilized: Proprietary glucose sensor technology, insulin infusion systems, and integrated device design.
- Primary Markets Targeted: Individuals with type 1 and type 2 diabetes who require insulin therapy.
Financials and Funding
PDT has secured over $8 million in funding through various grants and investments:
- Total Funds Raised: Approximately $8.2 million.
- Recent Funding Rounds:
- March 2025: Raised $2.1 million in a seed funding round.
- September 2024: Raised $1.54 million in a seed funding round.
- September 2023: Raised $500,000 in a seed funding round.
- Notable Investors: The Juvenile Diabetes Research Foundation (JDRF), National Institutes of Health (NIH), and The Leona M. and Harry B. Helmsley Charitable Trust.
- Utilization of Capital: Advancing product development, conducting clinical trials, and preparing for market entry.
Pipeline Development
PDT's primary pipeline candidate is the SynerG™ device, which integrates CGM and insulin delivery into a single unit. The device is currently in the prototype stage, with plans to seek FDA approval for human feasibility trials in the near future.
Technological Platform and Innovation
- Proprietary Technologies: Hollow glucose sensor technology that enables simultaneous insulin infusion and continuous glucose monitoring at a single site.
- Significant Scientific Methods: Development of specialized chemistry for glucose measurement at the insulin delivery site.
Leadership Team
- Robert Cargill: President and CEO. He has been instrumental in leading PDT's strategic direction and securing funding.
- Dr. W. Kenneth Ward: Chief Science Officer. He oversees the scientific and technological development of PDT's products.
Competitor and Market Profile
Market Insights and Dynamics
The diabetes management device market is experiencing significant growth, driven by the increasing prevalence of diabetes and the demand for more efficient management solutions.
Competitor Analysis
- Dexcom, Inc.: A leading provider of continuous glucose monitoring systems.
- Medtronic: Offers a range of diabetes management devices, including insulin pumps and CGMs.
- Tandem Diabetes Care, Inc.: Specializes in insulin pumps and related technologies.
Strategic Collaborations and Partnerships
PDT has partnered with the Juvenile Diabetes Research Foundation (JDRF) to develop advanced infusion set technology, receiving $1.14 million in funding to support this initiative.
Operational Insights
PDT differentiates itself through its innovative approach of combining CGM and insulin delivery into a single device, addressing the challenges of managing multiple devices and improving patient adherence. This integrated solution aims to enhance user experience and health outcomes.
Strategic Opportunities and Future Directions
PDT is focused on advancing the SynerG™ device through clinical trials, seeking FDA approval, and preparing for market launch. The company aims to expand its product offerings and explore additional partnerships to strengthen its position in the diabetes management market.
Contact Information
- Website: www.pacificdt.com
